Coherus Bio Sciences, Inc. - Understand $chrs stock

$CHRS Market Cap: $197 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$304.3M

TTM

Gross Margin

47.44%

TTM

Net Earnings

-$450.0K

TTM

Current Assets

$369.0M

Q3 2024

Current Liabilities

$295.6M

Q3 2024

Current Ratio

124.85%

Q3 2024

Total Assets

$505.0M

Q3 2024

Total Liabilities

$593.0M

Q3 2024

Book Value

-$87.97M

Q3 2024

Cash

$97.69M

Q3 2024

P/E

-437.8

Dec 04, 2024 EST

Free Cash Flow

-$12.92M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$257.2M	$211.0M	$326.6M	$475.8M	$356.1M	$0.00	$1.556M	$190.1M	$30.04M	$31.11M	$2.751M	$1.899M
YoY Change	21.89%	-35.37%	-31.37%	33.63%		-100.0%	-99.18%	532.82%	-3.42%	1030.72%	44.87%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$257.2M	$211.0M	$326.6M	$475.8M	$356.1M	$0.00	$1.556M	$190.1M	$30.04M	$31.11M	$2.751M	$1.899M
Cost Of Revenue	$159.0M	$70.08M	$57.59M	$37.67M	$17.08M
Gross Profit	$98.25M	$141.0M	$269.0M	$438.2M	$339.0M
Gross Profit Margin	38.19%	66.79%	82.36%	92.08%	95.2%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$192.0M	$198.5M	$169.7M	$139.1M	$137.0M	$94.18M	$71.30M	$51.60M	$36.00M	$17.60M	$7.500M	$5.500M
YoY Change	-3.26%	16.95%	22.03%	1.49%	45.51%	32.08%	38.19%	43.33%	104.55%	134.67%	36.36%
% of Gross Profit	195.43%	140.81%	63.1%	31.74%	40.42%
Research & Development	$109.4M	$199.4M	$363.1M	$142.8M	$94.19M	$110.2M	$162.4M	$254.4M	$213.1M	$78.22M	$31.28M	$34.89M
YoY Change	-45.11%	-45.1%	154.35%	51.57%	-14.56%	-32.11%	-36.18%	19.42%	172.37%	150.08%	-10.34%
% of Gross Profit	111.38%	141.43%	135.0%	32.58%	27.78%
Depreciation & Amortization	$3.200M	$3.699M	$3.454M	$2.900M	$3.300M	$3.200M	$3.400M	$3.000M	$1.900M	$674.0K	$404.0K	$221.0K
YoY Change	-13.49%	7.09%	19.1%	-12.12%	3.13%	-5.88%	13.33%	57.89%	181.9%	66.83%	82.81%
% of Gross Profit	3.26%	2.62%	1.28%	0.66%	0.97%
Operating Expenses	$301.5M	$397.8M	$532.8M	$281.8M	$231.2M	$204.4M	$233.7M	$306.0M	$249.1M	$95.79M	$38.74M	$40.42M
YoY Change	-24.23%	-25.33%	89.05%	21.89%	13.11%	-12.53%	-23.64%	22.85%	160.06%	147.23%	-4.14%
Operating Profit	-$203.2M	-$256.9M	-$263.9M	$156.3M	$107.8M	-$204.4M	-$232.1M	-$115.9M	-$219.1M	-$64.68M	-$35.99M	-$38.52M
YoY Change	-20.9%	-2.64%	-268.79%	45.05%	-152.72%	-11.94%	100.24%	-47.08%	238.68%	79.71%	-6.56%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	-$40.54M	$32.47M	$22.96M	$21.17M	$17.60M	$9.684M	$9.552M	$7.980M	$33.00K	$3.900M	$5.293M	$1.514M
YoY Change	-224.84%	41.44%	8.47%	20.25%	81.75%	1.38%	19.7%	24081.82%	-99.15%	-26.32%	249.6%
% of Operating Profit				13.54%	16.33%
Other Income/Expense, Net	$5.469M	$3.822M	-$283.0K	$554.0K	$2.608M	$4.691M	$3.402M	-$3.877M	-$4.838M	-$18.60M	-$12.35M	$7.000M
YoY Change	43.09%	-1450.53%	-151.08%	-78.76%	-44.4%	37.89%	-187.75%	-19.86%	-73.98%	50.58%	-276.41%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$238.3M	-$291.8M	-$287.1M	$135.7M	$92.78M	-$209.4M	-$238.3M	-$127.8M	-$223.9M	-$87.20M	-$53.60M	-$33.00M
YoY Change	-18.33%	1.62%	-311.56%	46.28%	-144.3%	-12.12%	86.45%	-42.92%	156.77%	62.69%	62.42%
Income Tax	-$380.0K	$0.00	$0.00	$3.500M	$2.900M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income				2.58%	3.13%
Net Earnings	-$237.9M	-$291.8M	-$287.1M	$132.2M	$89.83M	-$209.3M	-$238.2M	-$127.3M	-$223.3M	-$87.13M	-$53.64M	-$33.00M
YoY Change	-18.46%	1.62%	-317.1%	47.21%	-142.91%	-12.11%	87.04%	-42.96%	156.23%	62.46%	62.53%
Net Earnings / Revenue	-92.48%	-138.24%	-87.92%	27.79%	25.23%		-15306.56%	-66.98%	-743.18%	-280.12%	-1949.65%	-1737.76%
Basic Earnings Per Share	-$2.53	-$3.76	-$3.81	$1.85	$1.29	-$3.22	-$4.48
Diluted Earnings Per Share	-$2.53	-$3.76	-$3.81	$1.62	$1.23	-$3.22	-$4.48	-$3.038M	-$6.019M	-$10.62M	-$1.670M	-$1.028M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$117.7M	$191.7M	$417.2M	$541.2M	$177.7M	$72.40M	$126.9M	$124.9M	$158.2M	$150.4M	$39.60M	$14.50M
YoY Change	-38.57%	-54.05%	-22.91%	204.56%	145.44%	-42.95%	1.6%	-21.05%	5.19%	279.8%	173.1%
Cash & Equivalents	$102.9M	$63.55M	$417.2M	$541.2M	$177.7M	$72.40M	$126.9M	$124.9M	$158.2M	$150.4M	$39.60M	$14.50M
Short-Term Investments	$14.86M	$128.1M
Other Short-Term Assets	$34.76M	$40.80M	$24.46M	$25.00M	$13.50M	$10.40M	$18.60M	$34.60M	$37.60M	$24.50M	$5.800M	$10.10M
YoY Change	-14.81%	66.77%	-2.14%	85.19%	29.81%	-44.09%	-46.24%	-7.98%	53.47%	322.41%	-42.57%
Inventory	$130.1M	$38.79M	$37.64M	$44.20M	$9.800M	$1.700M
Prepaid Expenses
Receivables	$260.5M	$110.0M	$123.0M	$157.0M	$142.0M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$508.4M	$381.2M	$602.3M	$767.5M	$343.0M	$84.40M	$145.5M	$161.5M	$197.4M	$179.1M	$45.70M	$24.80M
YoY Change	33.35%	-36.71%	-21.52%	123.76%	306.4%	-41.99%	-9.91%	-18.19%	10.22%	291.9%	84.27%
Property, Plant & Equipment	$11.03M	$14.44M	$16.01M	$20.10M	$16.50M	$6.700M	$12.80M	$10.80M	$10.50M	$4.500M	$1.700M	$1.600M
YoY Change	-23.63%	-9.76%	-20.37%	21.82%	146.27%	-47.66%	18.52%	2.86%	133.33%	164.71%	6.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$49.56M	$79.24M	$57.44M	$50.50M	$45.90M	$4.800M	$800.0K	$2.700M	$900.0K	$100.0K	$0.00	$0.00
YoY Change	-37.45%	37.94%	13.75%	10.02%	856.25%	500.0%	-70.37%	200.0%	800.0%
Total Long-Term Assets	$121.2M	$99.61M	$77.01M	$74.10M	$65.90M	$15.10M	$17.10M	$17.00M	$15.00M	$8.100M	$1.700M	$1.700M
YoY Change	21.7%	29.35%	3.93%	12.44%	336.42%	-11.7%	0.59%	13.33%	85.19%	376.47%	0.0%
Total Assets	$629.6M	$480.8M	$679.3M	$841.6M	$408.9M	$99.50M	$162.6M	$178.5M	$212.4M	$187.2M	$47.40M	$26.50M
YoY Change
Accounts Payable	$35.22M	$11.53M	$16.16M	$15.20M	$26.00M	$15.30M	$15.50M	$19.70M	$25.90M	$8.800M	$3.300M	$2.200M
YoY Change	205.56%	-28.67%	6.31%	-41.54%	69.93%	-1.29%	-21.32%	-23.94%	194.32%	166.67%	50.0%
Accrued Expenses	$169.6M	$126.0M	$148.4M	$129.2M	$89.00M	$17.50M	$8.500M	$24.50M	$24.10M	$11.20M	$7.300M	$3.600M
YoY Change	34.66%	-15.13%	14.88%	45.17%	408.57%	105.88%	-65.31%	1.66%	115.18%	53.42%	102.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$721.0K	$1.191M	$741.0K	$600.0K							$4.200M	$0.00
YoY Change	-39.46%	60.73%	23.5%
Total Short-Term Liabilities	$169.6M	$138.7M	$165.3M	$145.7M	$115.0M	$33.30M	$28.40M	$56.40M	$106.0M	$51.80M	$53.70M	$11.30M
YoY Change	22.32%	-16.11%	13.47%	26.7%	245.35%	17.25%	-49.65%	-46.79%	104.63%	-3.54%	375.22%
Long-Term Debt	$473.4M	$472.5M	$408.8M	$404.9M	$178.4M	$103.1M	$101.6M	$100.3M	$0.00	$0.00	$0.00	$0.00
YoY Change	0.19%	15.58%	0.96%	126.96%	73.04%	1.48%	1.3%
Other Long-Term Liabilities	$180.0M	$7.095M	$7.503M	$10.10M	$10.40M	$1.700M	$2.100M	$2.500M	$113.3M	$68.70M	$36.10M	$6.100M
YoY Change	2437.21%	-5.44%	-25.71%	-2.88%	511.76%	-19.05%	-16.0%	-97.79%	64.92%	90.3%	491.8%
Total Long-Term Liabilities	$653.4M	$479.6M	$416.3M	$415.0M	$188.8M	$104.8M	$103.7M	$102.8M	$113.3M	$68.70M	$36.10M	$6.100M
YoY Change	36.24%	15.2%	0.31%	119.81%	80.15%	1.06%	0.88%	-9.27%	64.92%	90.3%	491.8%
Total Liabilities	$823.0M	$618.3M	$581.6M	$560.7M	$303.7M	$138.1M	$130.8M	$158.0M	$218.6M	$120.4M	$89.80M	$17.30M
YoY Change	33.12%	6.3%	3.73%	84.62%	119.91%	5.58%	-17.22%	-27.72%	81.56%	34.08%	419.08%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2015	2014	2013	2012
Basic Shares Outstanding	94.16M	77.63M	75.45M	71.41M	69.68M	65.03M	53.13M	37.13M	8.520M	4.828M	4.964M
Diluted Shares Outstanding	94.16M	77.63M	75.45M	83.49M	73.19M	65.03M	53.13M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $197.01 Million

About Coherus BioSciences, Inc.

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 235 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. The company markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.

Industry: Biological Products, (No Diagnostic Substances) Peers: Allovir, Inc. ANAPTYSBIO, INC ANAVEX LIFE SCIENCES CORP. Dyne Therapeutics, Inc. MANNKIND CORP NORTHWEST BIOTHERAPEUTICS INC Viridian Therapeutics, Inc.\DE SANGAMO THERAPEUTICS, INC Seres Therapeutics, Inc.